United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market (2025-2031) | Growth, Analysis, Outlook, Segmentation, Companies, Forecast, Value, Trends, Share, Industry, Size & Revenue, Competitive Landscape

Name: United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market (2025-2031) | Growth & Analysis
Creator: 6Wresearch
License: https://www.6wresearch.com/privacy-policy

Market Forecast By Drugs (Prolastin, Zemaira/Respreeza, Glassia, Aralast NP, Others), By Gene Type (Type PiZZ, Type PiMS, Type PiMZ, Others), By Application (Lung Disease, Liver Disease, Population Type, Adults and Pediatric), By End User (Hospitals, Specialty Clinics, Home Healthcare, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) And Competitive Landscape

Product Code: ETC9937508	Publication Date: Sep 2024	Updated Date: Aug 2025	Product Type: Market Research Report
Publisher: 6Wresearch	Author: Sumit Sagar	No. of Pages: 75	No. of Figures: 35	No. of Tables: 20

Key Highlights of the Report:

United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Outlook
Market Size of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, 2024
Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Revenues & Volume for the Period 2021- 2031
United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Trend Evolution
United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Drivers and Challenges
United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Price Trends
United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Porter's Five Forces
United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Industry Life Cycle
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Drugs for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Prolastin for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Zemaira/Respreeza for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Glassia for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Aralast NP for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Others for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Gene Type for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Type PiZZ for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Type PiMS for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Type PiMZ for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Others for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Application for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Lung Disease for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Liver Disease for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Population Type for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Adults and Pediatric for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By End User for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Hospitals for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Specialty Clinics for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Home Healthcare for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Others for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Distribution Channel for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Hospital Pharmacy for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Retail Pharmacy for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Online Pharmacy for the Period 2021- 2031
Historical Data and Forecast of United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume By Others for the Period 2021- 2031
United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Import Export Trade Statistics
Market Opportunity Assessment By Drugs
Market Opportunity Assessment By Gene Type
Market Opportunity Assessment By Application
Market Opportunity Assessment By End User
Market Opportunity Assessment By Distribution Channel
United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Top Companies Market Share
United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Competitive Benchmarking By Technical and Operational Parameters
United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Company Profiles
United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Key Strategic Recommendations

Frequently Asked Questions About the Market Study (FAQs):

How does 6Wresearch market report help businesses in making strategic decisions?

Do you also provide customisation in the market study?

1 Executive Summary

2 Introduction

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Overview

3.1 United Kingdom (UK) Country Macro Economic Indicators

3.2 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, 2021 & 2031F

3.3 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Industry Life Cycle

3.4 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Porter's Five Forces

3.5 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Drugs, 2021 & 2031F

3.6 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Gene Type, 2021 & 2031F

3.7 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Application, 2021 & 2031F

3.8 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By End User, 2021 & 2031F

3.9 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F

4 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Dynamics

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing awareness and diagnosis of alpha-1 antitrypsin deficiency (AATD) in the UK

4.2.2 Advancements in research and development of AATD augmentation therapies

4.2.3 Growing demand for personalized medicine and targeted treatments in the healthcare sector

4.3 Market Restraints

4.3.1 High cost associated with AATD augmentation therapy

4.3.2 Limited availability and accessibility of AATD treatment centers in the UK

4.3.3 Stringent regulatory requirements for approval and reimbursement of AATD therapies

5 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Trends

6 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Types

6.1 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Drugs

6.1.1 Overview and Analysis

6.1.2 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Drugs, 2021- 2031F

6.1.3 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Prolastin, 2021- 2031F

6.1.4 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Zemaira/Respreeza, 2021- 2031F

6.1.5 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Glassia, 2021- 2031F

6.1.6 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Aralast NP, 2021- 2031F

6.1.7 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F

6.2 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Gene Type

6.2.1 Overview and Analysis

6.2.2 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Type PiZZ, 2021- 2031F

6.2.3 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Type PiMS, 2021- 2031F

6.2.4 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Type PiMZ, 2021- 2031F

6.2.5 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F

6.3 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Application

6.3.1 Overview and Analysis

6.3.2 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Lung Disease, 2021- 2031F

6.3.3 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Liver Disease, 2021- 2031F

6.3.4 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Population Type, 2021- 2031F

6.3.5 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Adults and Pediatric, 2021- 2031F

6.4 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By End User

6.4.1 Overview and Analysis

6.4.2 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Hospitals, 2021- 2031F

6.4.3 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Specialty Clinics, 2021- 2031F

6.4.4 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Home Healthcare, 2021- 2031F

6.4.5 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F

6.5 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Distribution Channel

6.5.1 Overview and Analysis

6.5.2 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F

6.5.3 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F

6.5.4 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Online Pharmacy, 2021- 2031F

6.5.5 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F

7 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Import-Export Trade Statistics

7.1 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Export to Major Countries

7.2 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Imports from Major Countries

8 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Key Performance Indicators

8.1 Patient adherence rate to AATD augmentation therapy

8.2 Number of clinical trials evaluating new AATD therapies in the UK

8.3 Average time to diagnosis of AATD patients in the UK

9 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Opportunity Assessment

9.1 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Drugs, 2021 & 2031F

9.2 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Gene Type, 2021 & 2031F

9.3 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Application, 2021 & 2031F

9.4 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By End User, 2021 & 2031F

9.5 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F

10 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Competitive Landscape

10.1 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue Share, By Companies, 2024

10.2 United Kingdom (UK) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Competitive Benchmarking, By Operating and Technical Parameters

11 Company Profiles

12 Recommendations

13 Disclaimer

Belize Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market

Benin Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market

Bhutan Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market

Bolivia Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market

Bosnia and Herzegovina Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market

Global Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market

Global Go To Market Strategy - 2030

Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.

By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.

To discover high-growth global markets and optimize your business strategy:

Click Here